Friday, 21 Jul 2017

You are here

Limited Benefits with Intra-Discal Steroid Injections for Back Pain

A a randomized trial published in Annals of Internal Medicine shows that intradiscal glucocorticoid injection has limited (1 month) efficacy in treating low back pain (LBP) associated with active discopathy, yet decreased over time.

A 3 center study in France assessed efficacy of a single glucocorticoid intradiscal injection in patients with chronic low back pain with active discopathy. Patients were randomized to receive either glucocorticoid injection during discography (n = 67) or discography alone (n = 68).

Back pain was assessed after 2 days and at 1, 3, 6, and 12 months. Intradiscal glucocorticoid injection group were more apt to achieve a pain score of <40 (out of 100) compared to the control group (55.4% vs. 33.3%).

This study (and others) question the use of spinal injections in patients with active disc disease and LBP.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Requests Removal of OPANA-ER from the Market

The U.S. Food and Drug Administration has asked Endo International to withdraw Opana ER from the market, stating that benefits no longer outweigh its risks of this long-acting opioid.

A March 2017 advisory committee concluded that Opana ER, is not safe, and many have called for its removal.

Opana ER is twice as potent as oxycodone and has a high abuse potential when crushed and taken for a massive high effect by addicts.  

Ohio Sues Five Pharma Companies Over Opioid Epidemic

Ohio is suing five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers that has resulted in the current opioid epidemic. The Attorney General of Ohio, Mike DeWine, wants to hold big Pharma responsible for a deadly and costly opioid crisis.

Non-Prescribed Opioid Abuse by Young Adults

Journal of Addiction Medicine reported that young adults often are "self-medicated" to manage pain.

Spinal Manipulation Equal to NSAIDS for Acute Low Back Pain

JAMA has published a review of 15 RCTs (1711 patients) analyzing the role of spinal manipulation therapy in patients with acute low back pain. The authors found modest improvements in pain and function at up to 6 weeks, with temporary minor musculoskeletal harms.

Lyrica Fails in Sciatica Pain

Lyrica (pregabalin) was first approved in 2004 and since has been studied and approved for use in neuropathic pain (associated with diabetic neuropathy), postherpetic neuralgia, partial onset seizures, fibromyalgia and neuropathic pain with spinal cord injury. It is often used to manage chronic pain and neuropathic pain outside these indications.